Undisclosed inherited retinal disease program 2

About VeonGen Therapeutics

VeonGen Therapeutics is a private, pre-clinical stage biotech company leveraging three novel AAV-based gene therapy platforms to address significant limitations in the field. Its core focus is on inherited retinal diseases, with an internal pipeline built on technologies enabling less invasive administration, delivery of large genes, and modulation of multiple genes. The company, a spin-off from Ludwig-Maximilians-University Munich, combines strong academic science with industry-experienced leadership and seeks both internal development and strategic partnerships to expand into other therapeutic areas like neuroscience and metabolic diseases.

Therapeutic Areas

Other Inherited Retinal Disease Drugs